Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

Our VP of Scientific Affairs, L. Alison McInnes MD, MS, doesn't just publish research, she participates—in dream studies conducted by Boris Heifets, MD, PhD's and his lab at Stanford! For more details on this "dreamy" research and its implications for PTSD and depression treatment, read or listen to Alison's interview with Boris (link in comments below) 💭

We had a great time at the American College of Neuropsychopharmacology (ACNP) Annual Meeting showcasing real-world evidence and its role in advancing psychiatric care and drug development. Our team presented two posters: 1) A Retrospective Analysis of Ketamine Intravenous Therapy for PTSD in Real-World Care SettingsLed by Rob Berman, M.D. (Yale University, Osmind Strategic Advisor) & L. Alison McInnes MD, MS McInnes, M.D., MS (VP of Scientific Affairs, Osmind) 2) Examining the Factor Structure of the Transdiagnostic DSM-5-TR Level 1 Cross-Cutting Symptom Measure in Real-World Psychiatric OutpatientsPresented by Carlene MacMillan, MD, FCTMSS,DFAACAP(Chief Medical Officer, Osmind) in collaboration with the American Psychiatric Association These posters showcase the power of real-world evidence, including significant symptom reductions with ketamine therapy for PTSD, and the validation of tools like the DSM-5-TR Cross-Cutting Symptom Measure for personalized mental health assessment. Reach out at osmind.org/research to discuss how real-world data can support innovation in psychiatric drug development and clinical care.

🌊 "Surfing is about optimism... you're facing the horizon, looking at the contours of the water, hoping that this amazing wave is going to come." Our CEO, Lucia Huang's approach to mental healthcare innovation mirrors this philosophy of patience, observation, and optimism. At Osmind, we're tackling one of healthcare's biggest challenges: making mental health care more efficient and impactful. As Lucia notes, "Especially in healthcare, being 99% good is not necessarily good enough." This drives our commitment to excellence and precision. Our focus is clear: eliminating "pajama time"—the extra hours clinicians spend on documentation after seeing patients—and generating real-world evidence to advance mental health treatment. Key to our approach: - Building software that truly serves clinicians' needs - Automating data collection to track patient outcomes - Taking a measured, thorough approach to innovation - Working within existing healthcare frameworks to create lasting change The mental health crisis requires both urgency and precision. Like catching the perfect wave, it's about timing, patience, and unwavering optimism about what's possible. 🌟 Learn more about Lucia’s journey and our mission in this The Business Journals feature: https://lnkd.in/dhnCRNbp

Henry Winslow: What do you see as the most pressing issues facing the field, especially ketamine prescribers and therapists, today? L. Alison McInnes MD, MS: We need to regulate ourselves. This whole ‘wild west' situation with different practitioners, different protocols, and inadequate addressing of abuse potential can’t continue. We need to manage ketamine therapy systematically. That's why I'm co-chairing the standards committee at the American Society of Ketamine Physicians, Psychotherapists and Practitioners along with Samuel Ko, MD, MBA, FACEP, FAAEM, CEO and CMO of Reset Ketamine. We're working to establish the first U.S. consensus guidelines. We've created a voluntary pledge where providers agree to seven key practice points—things like proper informed consent, not selling packages of infusions, and protecting patient welfare. Then next year, we’ll be rolling out comprehensive guidelines that we've developed with a committee, looking at all the different protocols out there and the supporting literature. If we don't show evidence that we're willing to self-regulate, the ‘wild west' analogy will stick and we'll never get insurance coverage. Real-world effectiveness studies in over 6,000 patients show basically 50% response and 25% remission. Now, these estimates are an upper bound because real-world data are never complete. They don’t include people who drop out of treatment, likely because they didn't respond as well. But even with this caveat, those results are very impressive. We need these standards in place to move forward.

Osmind will be presenting two posters at this year's American College of Neuropsychopharmacology (ACNP) Annual Meeting! -"A Retrospective Analysis of Ketamine Intravenous Therapy for PTSD in Real-World Care Settings" Led by Rob Berman, M.D., (Yale University School of Medicine, Osmind Strategic Advisor) and L. Alison McInnes MD, MS L. Alison McInnes (VP of Scientific Affairs, Osmind) -"Examining the Factor Structure of the Transdiagnostic DSM-5-TR Level 1 Cross-Cutting Symptom Measure in Real World Psychiatric Outpatients" Presented by Carlene MacMillan, MD, FCTMSS,DFAACAP, (Chief Medical Officer, Osmind) in collaboration with the American Psychiatric Association. Will you be at ACNP? We'd love to connect and discuss how our real-world evidence capabilities can support psychiatric drug development.

💡Husseini Manji, M.D., F.R.C.P.C. on Transforming Mental Health Care: "I want to congratulate Osmind and the American Psychiatric Association. It's a fantastic project. I think the transdiagnostic approach is where we should be going." Think about this: Depression, bipolar disorder, and schizophrenia aren't neat, separate boxes. They can share common threads—like anhedonia and cognitive impairment—that cut across traditional diagnoses. With the transiagnostic approach, instead of treating disorders, we treat underlying symptoms. Instead of rigid diagnostic boxes, we see patterns. Instead of one-size-fits-all, we target specific needs. What a transdiagnostic approach enables: -Earlier intervention based on symptoms -More precise treatment pathways -Potentially broader access to effective therapies -Better outcomes for patients That's why our collaboration with the APA on transdiagnostic measures like the DSM-Level-1-Cross-Cutting Meaasure (DSM-XC) is so exciting. We're not just collecting data—we're laying the groundwork to reimagine how we understand and treat mental health conditions. The future of mental healthcare goes beyond labels. It's about precision, measurement, and treating what matters most to each patient.

At CNS Summit, our Chief Medical Officer, Carlene MacMillan, MD, FCTMSS,DFAACAP channeled the "Decades / Back to the Future" theme perfectly while presenting a poster on implementing measurement-based care in psychiatry. Using Osmind's Learning Health System, we helped 115 practices adopt the DSM-5-TR Cross-Cutting Measure, with usage growing from 143 to 2,124 implementations in just 5 months. Just as Doc Brown's DeLorean revolutionized time travel, technology is transforming how we measure and understand mental health. This collaboration with American Psychiatric Association shows how we're building psychiatry's tomorrow, today—making precision psychiatry a clinical reality. #CNSSummit2024

🏆 Happy to share: Osmind has been recognized by Gartner Digital Markets for excellence in mental health technology! We've been named to both the Capterra Mental Health Shortlist and Software Advice FrontRunners list for 2024. What makes this particularly meaningful? The recognition comes directly from clinician feedback. Here's what clinicians are saying: 💬 "Osmind is the perfect EMR for an interventional clinic. Includes the necessary forms and charting needed for accurate documentation and is very end-user friendly." 💬 "Great customer service. They understand our industry in a special way other programs can't." 💬 "I hate charting less with Osmind." This recognition fuels our mission to empower clinicians with the tools they need to deliver innovative mental health care. As we look ahead to 2025, we're more committed than ever to keeping pace with psychiatry's tomorrow. Thank you to our incredible community of clinicians who trust us to support their practice. Your feedback shapes everything we do.

We’re thrilled to announce a partnership with Osmind to advance the future of mental health treatment and research! This first-of-its kind partnership will bring together our Risk Evaluation and Mitigation Strategies with Osmind’s purpose-built mental health electronic health record platform to reduce REMS implementation burden, improve the quality of REMS data, and optimize safe medication use and health outcomes. Learn more about the partnership here: https://lnkd.in/euZufYeV #Osmind #PatientsFirst #Pharmacovigilance #DrugSafety #REMS #SafetyandRiskManagement